| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Gender | Female | Male | Male |
| Age at diagnosis – SIAD / MDS (years) | 70 / 74 | 66 / 69 | 71 / 71 |
| MDS | |||
| Type | MDS-EB2 | MDS-MLD | MDS-SLD |
| Cytogenetic | trisomy 14 | normal | normal |
| Mutations | No | No | ZRSR2, SF3B1 |
| IPSS-R | 6 | 2 | 3 |
| MDS risk | High-risk | Low-risk, EPO refractory | Low-risk |
| Hematological treatment | Azacytidine (complete hematological response) | Azacytidine (complete hematological response) | None |
| SIAD | |||
| Type | Polymyalgia rheumatica | Relapsing polychondritis and Sweet’s syndrome | Small-vessel vasculitis with arthralgia and skin involvements |
| Level of steroid dependence (prednisone equivalent, mg/day) | 15–30 | 15 | 15 |
| SAIDs treatments before ldIL-2 | None | Hydroxychloroquine Thalidomide Azathioprine Disulone Anakinra Tocilizumab Infliximab | Anakinra |
| SAIDs treatments response | — | No response or severe side effects | Severe side effects |
| Pattern of the Il-2 therapy | |||
| Induction | 1 M IU 5 consecutive days | 1,5 M IU 5 consecutive days | 1 M IU 5 consecutive days |
| Maintenance | 1 MIU every 2 weeks | 1 MIU every 2 weeks | 1 MIU every 2 weeks |
| Duration | 6 months | 6 months | 6 months |
| Duration of monitoring after the start of the lIL-2 therapy (months) | 12 | 12 | 6 |
| SIAD outcomes | |||
| Clinical remission | Yes | Yes | Remission at the time of IL2 beginning relapse at steroid tapering |
| Acute-phase reactants | Normalized | Partial (at least 50% decrease) | Persistent (CRP at 60 mg/l) |
| Steroid decrease | From 15 to 5 mg/day | From 15 to 6 mg/day | Relapse of steroid decrease |
| ldIL-2 related adverse events | None | Local skin reaction at site of injection | Local skin reaction at site of injection |
| Pattern of the Il-2 therapy |
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Gender | Female | Male | Male |
| Age at diagnosis – SIAD / MDS (years) | 70 / 74 | 66 / 69 | 71 / 71 |
| MDS | |||
| Type | MDS-EB2 | MDS-MLD | MDS-SLD |
| Cytogenetic | trisomy 14 | normal | normal |
| Mutations | No | No | ZRSR2, SF3B1 |
| IPSS-R | 6 | 2 | 3 |
| MDS risk | High-risk | Low-risk, EPO refractory | Low-risk |
| Hematological treatment | Azacytidine (complete hematological response) | Azacytidine (complete hematological response) | None |
| SIAD | |||
| Type | Polymyalgia rheumatica | Relapsing polychondritis and Sweet’s syndrome | Small-vessel vasculitis with arthralgia and skin involvements |
| Level of steroid dependence (prednisone equivalent, mg/day) | 15–30 | 15 | 15 |
| SAIDs treatments before ldIL-2 | None | Hydroxychloroquine Thalidomide Azathioprine Disulone Anakinra Tocilizumab Infliximab | Anakinra |
| SAIDs treatments response | — | No response or severe side effects | Severe side effects |
| Pattern of the Il-2 therapy | |||
| Induction | 1 M IU 5 consecutive days | 1,5 M IU 5 consecutive days | 1 M IU 5 consecutive days |
| Maintenance | 1 MIU every 2 weeks | 1 MIU every 2 weeks | 1 MIU every 2 weeks |
| Duration | 6 months | 6 months | 6 months |
| Duration of monitoring after the start of the lIL-2 therapy (months) | 12 | 12 | 6 |
| SIAD outcomes | |||
| Clinical remission | Yes | Yes | Remission at the time of IL2 beginning relapse at steroid tapering |
| Acute-phase reactants | Normalized | Partial (at least 50% decrease) | Persistent (CRP at 60 mg/l) |
| Steroid decrease | From 15 to 5 mg/day | From 15 to 6 mg/day | Relapse of steroid decrease |
| ldIL-2 related adverse events | None | Local skin reaction at site of injection | Local skin reaction at site of injection |
| Pattern of the Il-2 therapy |
EB2: excess blasts-2; F: female; ldIL-2: low dose IL-2; M: male; MIU: million-unit dose; MDS: myelodysplastic syndrome; MLD: multineage dysplasia; SIAD: systemic inflammatory and autoimmune disease; SLD: single lineage dysplasia.
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Gender | Female | Male | Male |
| Age at diagnosis – SIAD / MDS (years) | 70 / 74 | 66 / 69 | 71 / 71 |
| MDS | |||
| Type | MDS-EB2 | MDS-MLD | MDS-SLD |
| Cytogenetic | trisomy 14 | normal | normal |
| Mutations | No | No | ZRSR2, SF3B1 |
| IPSS-R | 6 | 2 | 3 |
| MDS risk | High-risk | Low-risk, EPO refractory | Low-risk |
| Hematological treatment | Azacytidine (complete hematological response) | Azacytidine (complete hematological response) | None |
| SIAD | |||
| Type | Polymyalgia rheumatica | Relapsing polychondritis and Sweet’s syndrome | Small-vessel vasculitis with arthralgia and skin involvements |
| Level of steroid dependence (prednisone equivalent, mg/day) | 15–30 | 15 | 15 |
| SAIDs treatments before ldIL-2 | None | Hydroxychloroquine Thalidomide Azathioprine Disulone Anakinra Tocilizumab Infliximab | Anakinra |
| SAIDs treatments response | — | No response or severe side effects | Severe side effects |
| Pattern of the Il-2 therapy | |||
| Induction | 1 M IU 5 consecutive days | 1,5 M IU 5 consecutive days | 1 M IU 5 consecutive days |
| Maintenance | 1 MIU every 2 weeks | 1 MIU every 2 weeks | 1 MIU every 2 weeks |
| Duration | 6 months | 6 months | 6 months |
| Duration of monitoring after the start of the lIL-2 therapy (months) | 12 | 12 | 6 |
| SIAD outcomes | |||
| Clinical remission | Yes | Yes | Remission at the time of IL2 beginning relapse at steroid tapering |
| Acute-phase reactants | Normalized | Partial (at least 50% decrease) | Persistent (CRP at 60 mg/l) |
| Steroid decrease | From 15 to 5 mg/day | From 15 to 6 mg/day | Relapse of steroid decrease |
| ldIL-2 related adverse events | None | Local skin reaction at site of injection | Local skin reaction at site of injection |
| Pattern of the Il-2 therapy |
| . | Patient 1 . | Patient 2 . | Patient 3 . |
|---|---|---|---|
| Gender | Female | Male | Male |
| Age at diagnosis – SIAD / MDS (years) | 70 / 74 | 66 / 69 | 71 / 71 |
| MDS | |||
| Type | MDS-EB2 | MDS-MLD | MDS-SLD |
| Cytogenetic | trisomy 14 | normal | normal |
| Mutations | No | No | ZRSR2, SF3B1 |
| IPSS-R | 6 | 2 | 3 |
| MDS risk | High-risk | Low-risk, EPO refractory | Low-risk |
| Hematological treatment | Azacytidine (complete hematological response) | Azacytidine (complete hematological response) | None |
| SIAD | |||
| Type | Polymyalgia rheumatica | Relapsing polychondritis and Sweet’s syndrome | Small-vessel vasculitis with arthralgia and skin involvements |
| Level of steroid dependence (prednisone equivalent, mg/day) | 15–30 | 15 | 15 |
| SAIDs treatments before ldIL-2 | None | Hydroxychloroquine Thalidomide Azathioprine Disulone Anakinra Tocilizumab Infliximab | Anakinra |
| SAIDs treatments response | — | No response or severe side effects | Severe side effects |
| Pattern of the Il-2 therapy | |||
| Induction | 1 M IU 5 consecutive days | 1,5 M IU 5 consecutive days | 1 M IU 5 consecutive days |
| Maintenance | 1 MIU every 2 weeks | 1 MIU every 2 weeks | 1 MIU every 2 weeks |
| Duration | 6 months | 6 months | 6 months |
| Duration of monitoring after the start of the lIL-2 therapy (months) | 12 | 12 | 6 |
| SIAD outcomes | |||
| Clinical remission | Yes | Yes | Remission at the time of IL2 beginning relapse at steroid tapering |
| Acute-phase reactants | Normalized | Partial (at least 50% decrease) | Persistent (CRP at 60 mg/l) |
| Steroid decrease | From 15 to 5 mg/day | From 15 to 6 mg/day | Relapse of steroid decrease |
| ldIL-2 related adverse events | None | Local skin reaction at site of injection | Local skin reaction at site of injection |
| Pattern of the Il-2 therapy |
EB2: excess blasts-2; F: female; ldIL-2: low dose IL-2; M: male; MIU: million-unit dose; MDS: myelodysplastic syndrome; MLD: multineage dysplasia; SIAD: systemic inflammatory and autoimmune disease; SLD: single lineage dysplasia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
